TrademarkIQ íconeTrademarkIQ
Voltar para busca
Dado oficial do USPTO

CPO

Sabia que essa marca já está registrada no Estados Unidos?

Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.

Active USPTO registrationTipo: MistaEscritório: US

Snapshot rápido

CPO

ST13

US500000079317618

Classe

5

Pedido

79317618

Registro

7050981

Diagnóstico de risco e oportunidade

Leitura executiva para decisão de naming, protocolo e monitoramento.

Atenção: há risco ativo

Situação USPTO

Active USPTO registration

Tipo de processo

Pedido e registro

Eventos registrados

42

Atualização mais recente

12/09/2023

Classificação

Registrada

Tipo de marca

Mista

Classes Nice

5

Data de depósito

22/04/2021

Data de registro

16/05/2023

Data de expiração

-

Ação recomendada

Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.

Próximo passo

Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.

Dados completos do processo

Campos estruturados da autoridade responsável e do histórico oficial.

Data da situação

16/05/2023

Última transação

16/05/2023

Escritório responsável

United States Patent and Trademark Office

Código da situação

700

Cadastro oficial

Principal Register

Código do desenho

3

Tipo de titular

99

Localização do titular

AU

Examinador

CORNWELL, ANDREA B

Unidade examinadora

M60

Localização atual

PUBLICATION AND ISSUE SECTION

Descrição da marca

The mark consists of the stylized wording "CPO" to the right of a stylized concentric oval and circle design.

Titulares e representantes

Titulares

Pharmako Biotechnologies Pty Limited

Representantes

Jennifer A. Visintine Thompson Coburn LLP

Classificação técnica

Classes Nice

Classe 5

Códigos Vienna

Sem códigos Vienna disponíveis.

Produtos e serviços

Classe 5

Medicines in tablet form for the treatment of nutritional and vitamin deficiencies; medicated preparations in the form of powders, namely, drug delivery agents in the form of powders that provide controlled release of the active ingredients for a wide variety of pharmaceuticals; veterinary preparations in the form of powder, namely, drug delivery agents in the form of powders that provide controlled release of the active ingredients for a wide variety of veterinary pharmaceuticals; veterinary preparations, namely, dietary and nutritional supplements for veterinary use; medical preparations, namely, drug delivery agents consisting of compounds that facilitate delivery of a wide range of pharmaceuticals; medicated food additives being pharmaceutical products that facilitate or increase the absorption of vitamins and minerals; medicated supplements for foodstuffs for animals; medicated supplements for foodstuffs for human consumption for medical purposes; medicated skin care preparations; medicated preparations for use as supplements for food for medical purposes; powders for skin care for medical use; drug delivery agents in the form of capsules that provide controlled release of the active ingredients for a wide variety of pharmaceuticals; medicinal oils containing vitamins and minerals; oils adapted for pharmaceutical purposes, namely, for the increasing the bioavailability and absorption of active ingredients in foodstuffs and medicines; oils for use in medicine, namely, medicated oils containing vitamins and minerals; dietary supplements; pharmaceutical preparations, namely, drug delivery agents consisting of compounds that facilitate delivery of a wide range of pharmaceuticals; dietetic foods adapted for medical purposes; dietetic substances namely foods, beverages and supplements adapted for medical use; dietetic substances, namely foods, beverages and supplements for veterinary use; dietary supplements; dietary supplements for animals; nutritional meal replacements, namely beverages and supplements adapted for medical use; nutritional preparations for medical use, namely, medications used for the delivery and absorption of nutrients; nutritional supplements; medicinal healthcare products, namely, dietary supplements with medicinal properties that increase the bioavailability and absorption of active ingredients in foodstuffs and medicines; chemical products for use in medical or veterinary biotechnology, namely, chemical preparations for increasing bioavailability and absorption of active ingredients in foodstuffs and medicines; biotechnological preparations for medical use, namely, mixed biological preparations for the prevention and treatment of nutritional deficiencies; chemical products for medical use, namely, chemical reagents for medical purposes; dietary supplements with a cosmetic effect; medicated skin creams for personal care; medicated preparations for the regeneration of the skin; medicated preparations for the treatment of the skin; medicated preparations for use in the bath; medicated creams for the face

Publicações

Histórico de despachos e eventos da marca no USPTO.

42 publicações encontradas

FINO

FINAL DECISION TRANSACTION PROCESSED BY IB

12/09/2023

FICS

FINAL DISPOSITION NOTICE SENT TO IB

17/08/2023

FIMP

FINAL DISPOSITION PROCESSED

17/08/2023

FICR

FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB

16/08/2023

NRCC

NOTICE OF REGISTRATION CONFIRMATION EMAILED

16/05/2023

R.PR

REGISTERED-PRINCIPAL REGISTER

16/05/2023

NPUB

OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED

28/02/2023

PUBO

PUBLISHED FOR OPPOSITION

28/02/2023

GPNX

NOTIFICATION PROCESSED BY IB

27/02/2023

OPNS

NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB

08/02/2023

OP2R

NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB

08/02/2023

NONP

NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED

08/02/2023

OPNX

NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB

06/02/2023

CNSA

APPROVED FOR PUB - PRINCIPAL REGISTER

26/01/2023

OPNS

NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB

18/01/2023

TEME

TEAS/EMAIL CORRESPONDENCE ENTERED

18/01/2023

CRFA

CORRESPONDENCE RECEIVED IN LAW OFFICE

18/01/2023

ERFR

TEAS REQUEST FOR RECONSIDERATION RECEIVED

18/01/2023

OPNR

NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB

18/01/2023

NREP

NEW REPRESENTATIVE AT IB RECEIVED

17/09/2022

GNFN

NOTIFICATION OF FINAL REFUSAL EMAILED

28/07/2022

GNFR

FINAL REFUSAL E-MAILED

28/07/2022

CNFR

FINAL REFUSAL WRITTEN

28/07/2022

TEME

TEAS/EMAIL CORRESPONDENCE ENTERED

14/07/2022

CRFA

CORRESPONDENCE RECEIVED IN LAW OFFICE

13/07/2022

TROA

TEAS RESPONSE TO OFFICE ACTION RECEIVED

13/07/2022

CHAN

APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED

08/07/2022

TCCA

TEAS CHANGE OF CORRESPONDENCE RECEIVED

08/07/2022

ECDR

TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS

08/07/2022

ARAA

ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED

08/07/2022

REAP

TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED

08/07/2022

COAR

TEAS CHANGE OF OWNER ADDRESS RECEIVED

08/07/2022

RFNT

REFUSAL PROCESSED BY IB

30/01/2022

RFCS

NON-FINAL ACTION MAILED - REFUSAL SENT TO IB

13/01/2022

RFRR

REFUSAL PROCESSED BY MPU

13/01/2022

RFCR

NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW

22/12/2021

CNRT

NON-FINAL ACTION WRITTEN

21/12/2021

DOCK

ASSIGNED TO EXAMINER

17/12/2021

MAFR

APPLICATION FILING RECEIPT MAILED

24/08/2021

NWOS

NEW APPLICATION OFFICE SUPPLIED DATA ENTERED

18/08/2021

LIMI

LIMITATION FROM ORIGINAL APPLICATION ENTERED

16/08/2021

REPR

SN ASSIGNED FOR SECT 66A APPL FROM IB

12/08/2021

Proteção contínua da sua marca

Seja avisado a cada novo depósito que ameace CPO ou a sua marca.

Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.